2026
From JP Morgan to the Next Wave: What’s Driving Biotech in 2026
J.P. Morgan Healthcare Conference; biotech trends 2026; M&A activity; oncology; neuropsychology; hematology; artificial intelligence; drug discovery; investment; regulatory science
Novartis to Acquire RNA Drugmaker Avidity Biosciences in $12 Billion Deal
Novartis; Avidity Biosciences; acquisition; RNA therapeutics; neuromuscular diseases; Duchenne muscular dystrophy; myotonic dystrophy type 1; facioscapulohumeral muscular dystrophy; AOC platform; SpinCo; biotech; xRNA strategy; 2026 closing